<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00960765</url>
  </required_header>
  <id_info>
    <org_study_id>CPL200907A</org_study_id>
    <nct_id>NCT00960765</nct_id>
  </id_info>
  <brief_title>Endotoxin and Intestinal Flora Before and After Gastric Bypass or Banding in Diabetics</brief_title>
  <official_title>Comparison Of Endotoxin Concentration And Intestinal Microbiologic Flora Before And After Roux-En-Y Gastric Bypass Or Gastric Banding Surgery In Morbidly Obese Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CPL Associates</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Synergy Bariatrics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sisters of Charity Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The New York State Center of Excellence in Bioinformatics &amp; Life Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CPL Associates</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research project is designed to investigate endotoxin (a toxin present in the wall of&#xD;
      certain kinds of bacteria) levels and the type of bacteria present in the intestine before&#xD;
      and after Roux-en-Y gastric bypass or gastric banding surgery in patients that meet the&#xD;
      classification for morbid obesity (body mass index &gt;40 kg/m2) and type 2 diabetes. It is&#xD;
      known that the type of bacteria present in the intestines of normal weight and obese&#xD;
      individuals are different, and it is also known that people with obesity and type 2 diabetes&#xD;
      have higher levels of endotoxin. It has been shown that the bacteria change over the long run&#xD;
      after Roux-en-Y gastric bypass surgery, but the short-term effects are not known and the&#xD;
      endotoxin levels after this procedure have never been studied.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evidence exists that (i) morbidly obese, T2D patients undergoing RYGB are highly likely to&#xD;
      resolve T2D symptoms or dramatically reduce oral and/or insulin requirements, (ii) metabolic&#xD;
      endotoxemia may incite the pathologic conditions of low-grade inflammation and subsequently&#xD;
      insulin resistance, obesity and T2D, (iii) significant intestinal microbiologic flora&#xD;
      differences exist between normal weight and obese/diabetic individuals, and (iv) RYGB alters&#xD;
      long-term intestinal microbiologic flora. Therefore, it is logical to evaluate short- and&#xD;
      long-term circulating endotoxin concentrations and intestinal microbiologic flora in context&#xD;
      with weight loss and restoration of euglycemia to expand our knowledge of the mechanism of&#xD;
      the benefits observed following RYGB.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">15</enrollment>
  <condition>Obesity, Morbid</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Gastric Bypass</condition>
  <arm_group>
    <arm_group_label>Roux-En-Y Gastric Bypass</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Gastric Banding</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Sucessful Response to RYGB</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Failed Response to RYGB</arm_group_label>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum, urine, stool&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Morbidly obese (BMI &gt; 40 kg/m2) patients with T2D&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years of age&#xD;
&#xD;
          -  Morbid obesity (BMI &gt; 40 kg/m2)&#xD;
&#xD;
          -  Confirmed T2D diagnosis/date of onset&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years of age&#xD;
&#xD;
          -  BMI &lt; 40 kg/m2&#xD;
&#xD;
          -  Type 1 diabetes&#xD;
&#xD;
          -  Chronic use of non-steroidal anti-inflammatory agents (NSAIDs)&#xD;
&#xD;
          -  Chronic use of systemic corticosteroids&#xD;
&#xD;
          -  Anticipated inability to maintain current statin, angiotensin converting enzyme&#xD;
             inhibitor (ACEI), or angiotensin receptor blocking agent (ARB) regimen&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph A Caruana, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Synergy Bariatrics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sisters of Charity Hospital</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synergy Bariatrics</name>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <zip>14221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>August 17, 2009</study_first_submitted>
  <study_first_submitted_qc>August 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2009</study_first_posted>
  <last_update_submitted>January 27, 2016</last_update_submitted>
  <last_update_submitted_qc>January 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>CPL Associates</investigator_affiliation>
    <investigator_full_name>Scott Monte</investigator_full_name>
    <investigator_title>Program Director</investigator_title>
  </responsible_party>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <keyword>Gastric Bypass</keyword>
  <keyword>Gastric Banding</keyword>
  <keyword>Endotoxin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

